Related Experiment Video

Updated: Aug 23, 2026

Intrathecal Vector Delivery in Juvenile Rats via Lumbar Cistern Injection
04:38

Intrathecal Vector Delivery in Juvenile Rats via Lumbar Cistern Injection

Published on: March 29, 2024

Intravenous, non-viral RNAi gene therapy of brain cancer

William M Pardridge1

  • 1Department of Medicine, UCLA, Warren Hall 13-164, 900 Veteran Ave, Los Angeles, CA 90024, USA. wpardridge@mednet.ucla.edu

Expert Opinion on Biological Therapy
|July 23, 2004
PubMed

Insights

This study demonstrates a novel method for delivering RNA interference (RNAi) therapeutics to treat brain cancer. Pegylated immunoliposomes effectively deliver plasmid DNA for short hairpin RNA (shRNA) gene knockdown, significantly improving survival rates in preclinical models.

Area of Science:

  • Oncology
  • Gene Therapy
  • Nanotechnology

Background:

  • RNA interference (RNAi) holds promise for cancer treatment, but therapeutic application is limited by RNA instability and delivery challenges.
  • Plasmid DNA can be engineered to express short hairpin RNA (shRNA), mimicking microRNAs for gene knockdown.
  • Developing effective in vivo delivery systems is crucial for realizing the potential of RNAi-based cancer therapeutics.

Purpose of the Study:

  • To evaluate a novel non-viral gene-targeting technology for RNAi-based gene therapy of brain cancer.
  • To assess the feasibility of using receptor-specific pegylated immunoliposomes (PILs) for delivering plasmid DNA encoding shRNA.
  • To determine the efficacy of this approach in reducing oncogene expression and extending survival in preclinical brain cancer models.

Main Methods:

  • Development of receptor-specific pegylated immunoliposomes (PILs) to encapsulate plasmid DNA expressing shRNA.
  • Intravenous administration of PILs in adult rats and mice with intracranial brain cancer.
  • Evaluation of gene knockdown efficacy targeting brain tumour-specific genes.
  • Assessment of survival rates in mice with intracranial human brain cancer treated with PILs carrying shRNA against the human epidermal growth factor receptor.

Main Results:

  • Achieved up to 90% knockdown of brain tumour-specific gene expression with a single intravenous injection.
  • Demonstrated significant extension of survival, nearly 90%, in mice with intracranial human brain cancer via weekly PILs injections.
  • Confirmed the feasibility and efficacy of the PILs-based delivery system for RNAi therapeutics.

Conclusions:

  • Pegylated immunoliposomes (PILs) represent a viable non-viral delivery system for RNAi-based gene therapy in brain cancer.
  • This technology enables effective gene knockdown and significantly improves survival outcomes in preclinical models.
  • RNAi-based gene therapy, potentially combined with tumor suppressor gene replacement, offers a promising polygenic strategy for cancer treatment.

More Related Videos

Lumbar Intrathecal Injection of Gene Therapy Vectors for Central Nervous System Targeting in Mice and Rats05:09

Lumbar Intrathecal Injection of Gene Therapy Vectors for Central Nervous System Targeting in Mice and Rats

Published on: May 16, 2025

Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models06:16

Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models

Published on: March 16, 2022

Related Concept Videos

siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...